At initial diagnosis, the search for potential targets can be guided by clinical information and tumor histology, focusing on early oncogenic events that remain present throughout the course of the disease, for example the PAX3-FOXO1 fusion in rhabdomyosarcoma. This evidence concerns the gene FOXO1 and neoplasm.